Article Sidebar
Views PDF: 2
CLINICAL, PARACLINICAL CHARACTERISTICS AND INFLAMMATION-SCORES IN LATE STAGE NON-SMALL CELL LUNG CANCER
Main Article Content
Abstract
Abstract
Objectives: To describe clinical and paraclinical characteristics and some inflammatory-scores (NLR, PLS, SII) in late stage non-small cell lung cancer patients at Military Hospital 103. Methods: A retrospective and prospective, crosssectional study on 109 inpatients diagnosed with late stage non-small cell lung cancer at the Respiratory Center, Military Hospital 103 from January 2019 to September 2024. Results: The mean age of patiens were 65.43 ± 12.09 years, with a higher proportion of males. Patients have a variety of clinical symptoms, most common subjective symptoms were cough (86.33%) and chest pain (53.33%). The most common sites of metastasis were the pleura (42.20%), contralateral lung (22.93%), abdomen (19.27%) and bones (18.35%). 79,82% of patients were in stage IV, and adenocarcinoma accounted for 75.23% of the cases. On chest CT, the most frequent findings were pleural effusion (50/109) and round-shaped opacity (92/109). The median value of NLR was 3.467, with a range of 0.739 to 36.943. The median values for PLR and SII were 166.379 and 981.167, respectively, with PLR ranging from 35.494 to 1127.027 and SII from 232.214 to 14831.676. Conclusion: Patients with late stage non-small cell lung cancer were higher rate in male, high mean age with diversified clinical symptoms, predominantly adenocarcinoma, and typically presents with round-shaped opacity on chest CT. The median values of NLR, PLR, and SII were 3.467, 166.379, and 981.167, respectively.
Article Details
Keywords
Non small cell lung cancer, NLR (neutrophil to lympho ratio), PLR (platelet to lymphocyte ratio), SII (systemic immune-inflammation index)
References
2. Riely Gregory, J Wood, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Journal of the National Comprehensive Cancer Network. 2024; 22(4):249-274.
3. Coussens LM and Werb Z. Inflammation and cancer. Nature, 2002; 420(6917):860-867.
4. Nguyễn Thị Lan Anh. Nghiên cứu đặc điểm đột biến gen EGFR và mối liên quan với lâm sàng, cận lâm sàng ở BN ung thư phổi biểu mô. Luận án Tiến sĩ Y học, Học viện Quân y. 2017.
5. Nguyễn Đức Nhơn, Nguyễn Hồng Phong. Nghiên cứu tình hình và một số yếu tố liên quan đến đột biến gen EGFR trên BN ung thư biểu mô tuyến nguyên phát của phổi tại Bệnh viện Ung bướu thành phố Cần Thơ năm 2021. Tạp chí Y Dược học Cần Thơ. 2023; 41:120-127.
6. Hoesel B and Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013; 12:86.
7. O'Brien SM, Klampatsa A, Thompson JC, et al. Function of human tumor-infiltrating lymphocytes in early-stage non-small cell lung cancer. Cancer Immunol Res. 2019; 7(6):896-909.
8. Shu L, Lin S, Zhou S, et al. Glycan-Lectin interactions between platelets and tumor cells drive hematogenous metastasis. Platelets. 2024; 35(1):2315037.
9. Tong YS, Tan J, Zhou XL, et al. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med. 2017; 15(1):221.
10. Huỳnh Đức Lê và CS. Nghiên cứu giá trị chỉ số NLR, PLR trong dự báo đáp ứng điều trị không tế bào nhỏ với phác đồ hóa chất có Platinum. Tạp chí Y học Việt Nam. 2022; 519(2):296-301.